Affimed N.V. 0HL9.L Stock
Affimed N.V. Price Chart
Affimed N.V. 0HL9.L Financial and Trading Overview
Affimed N.V. stock price | 5.14 USD |
Previous Close | 0.73 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 3.31 USD |
Volume | 398.24K USD |
Avg. Volume | 3.9K USD |
Market Cap | N/A |
Beta (5Y Monthly) | 2.515492 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.659 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0HL9.L Valuation Measures
Enterprise Value | -34588464 USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.8353222 |
Enterprise Value/Revenue | -0.876 |
Enterprise Value/EBITDA | 0.34 |
Trading Information
Affimed N.V. Stock Price History
Beta (5Y Monthly) | 2.515492 |
52-Week Change | -72.70% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.31 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 0.81 USD |
200-Day Moving Average | 1.65 USD |
0HL9.L Share Statistics
Avg. Volume (3 month) | 3.9K USD |
Avg. Daily Volume (10-Days) | 4.94K USD |
Shares Outstanding | N/A |
Float | 125.56M |
Short Ratio | N/A |
% Held by Insiders | 4.70% |
% Held by Institutions | 61.92% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -256.51% |
Operating Margin (ttm) | -259.11% |
Gross Margin | 45.56% |
EBITDA Margin | -257.41% |
Management Effectiveness
Return on Assets (ttm) | -35.41% |
Return on Equity (ttm) | -83.56% |
Income Statement
Revenue (ttm) | 39.5M USD |
Revenue Per Share (ttm) | 0.27 USD |
Quarterly Revenue Growth (yoy) | -40.69% |
Gross Profit (ttm) | N/A |
EBITDA | -101675000 USD |
Net Income Avi to Common (ttm) | -101322000 USD |
Diluted EPS (ttm) | -0.659 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 155.85M USD |
Total Cash Per Share (mrq) | 1.04 USD |
Total Debt (mrq) | 16.72M USD |
Total Debt/Equity (mrq) | 13.37 USD |
Current Ratio (mrq) | 5.21 |
Book Value Per Share (mrq) | 0.838 |
Cash Flow Statement
Operating Cash Flow (ttm) | -109716000 USD |
Levered Free Cash Flow (ttm) | -72079504 USD |
Profile of Affimed N.V.
Country | United Kingdom |
State | N/A |
City | Heidelberg |
Address | Technologiepark |
ZIP | 69120 |
Phone | 49 6221 6743 60 |
Website | https://www.affimed.com |
Industry | |
Sector(s) | |
Full Time Employees | 219 |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Q&A For Affimed N.V. Stock
What is a current 0HL9.L stock price?
Affimed N.V. 0HL9.L stock price today per share is 5.14 USD.
How to purchase Affimed N.V. stock?
You can buy 0HL9.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Affimed N.V.?
The stock symbol or ticker of Affimed N.V. is 0HL9.L.
How many shares does Affimed N.V. have in circulation?
The max supply of Affimed N.V. shares is 0.
What is Affimed N.V. Price to Earnings Ratio (PE Ratio)?
Affimed N.V. PE Ratio is now.
What was Affimed N.V. earnings per share over the trailing 12 months (TTM)?
Affimed N.V. EPS is -0.659 USD over the trailing 12 months.